ZURICH (Reuters) - Roche (>> Roche Holding Ltd.) on Monday said its Foundation Medicine (>> Foundation Medicine Inc) unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumours and guide them to effective therapies.

Roche, which owns 58 percent of Foundation, is hoping to use the FoundationOne CDx assay to personalise cancer care, where treatment is better tailored to the specific molecular characteristics of each patient's disease.

(Reporting by John Miller)

Stocks treated in this article : Roche Holding Ltd., Foundation Medicine Inc